The ETP Nanomedicine, an initiative led by industry and set up together with the European Commission is addressing the application of nanotechnology to achieve breakthroughs in healthcare.
Nanomedicine exploits the improved and often novel physical, chemical and biological properties of materials at the nanometer scale. Nanomedicine has the potential to enable early detection and prevention, and to essentially improve diagnosis, treatment and follow-up of diseases.
The ETP supports its members in coordinating their joint research efforts and improving communication amongst the members as well as towards the European Commission and the European Member States.
This event is organised by the European Medicines Agency (EMA) and is going to be held on 26-27 April in Canary Wharf, London.
Nano4Med is a one day workshop, part of the Minatec Crossroads’10 week of events. It is jointly organised by CEA-Leti and the Grenoble cluster on nanobiotechnology, NanoBio.
Interested applicants are encouraged to initiate scientific contacts with potential project consortium partners for applications.
This event is organised by ETP Nanomedicine and will give the ETP members and the wider Nanomedicine community the opportunity to get together and to exchange ideas for future common proposals in the framework of several relevant European calls in 2010.
There are two new initiatives for funding SMEs: CORNET and EraSME. CORNET supports trans-national European co-operation between SME associations, SMEs and R&D performers. EraSME supports trans-national research co-operation between individual SMEs and RTOs.
TOWARDS A STRATEGIC NANOTECHNOLOGY ACTION PLAN (SNAP) 2010-2015
A new LinkedIn group "ETP-Nanomedicine" has been created. It is open for all ETP Members.
The ETP Nanomedicine has introduced a new section on its website featuring job offers in the area of nanomedicine.
The expert report elaborated by the ETP Nanomedicine together with the European Commission and the support of distinguished experts from academia and industry has been published.
A contribution by the ETP Nanomedicine Executive Board Member Mike Eaton, UCB, UK.
